tirzepatide in heart failure ESC 2025: study supports use of semaglutide, cardiometabolic HFpEF patients Lower Risk of Cardiovascular Death

The most frequent reported adverse events were gastrointestinal, including but not limited to nausea (17% to 22% tirzepatide versus 18% semaglutide), diarrhea (13% to 16% tirzepatide versus 12% semaglutide), and vomiting (6% to 10% tirzepatide versus 8% semaglutide)

Animal Studies and Their Limitations Animal studies on tirzepatide have shown some concerning effects, such as changes in the development of fetuses

These products are not intended to be drugs that diagnose, treat, cure, or prevent any disease or condition

It reports 15-18% average loss of baseline body weight over 68 weeks, converting that to roughly 30-36 pounds for a 200-pound patient and 22-27 pounds for a 150-pound patient